MGC Pharmaceuticals Ltd (ASX: MXC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

MGC Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $98.06 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 2.32 billion
Earnings per share -0.008
Dividend per share N/A
Year To Date Return 60.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

MGC Pharmaceuticals Ltd (ASX: MXC)
Latest News

MXC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy within the international phytocannabinoid-derived and plant-derived medicines industry. Its operations comprise one segment, being production and supply of medicinal cannabis products. The company generates most of its revenue from Slovenia.

MXC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
22 Jul 2021 $0.04 $0.00 0.00% 2,704,535 $0.04 $0.04 $0.04
21 Jul 2021 $0.04 $0.00 0.00% 5,210,515 $0.04 $0.04 $0.04
20 Jul 2021 $0.04 $0.00 0.00% 4,466,467 $0.04 $0.04 $0.04
19 Jul 2021 $0.04 $0.00 0.00% 4,806,769 $0.04 $0.04 $0.04
16 Jul 2021 $0.04 $0.00 0.00% 5,427,151 $0.04 $0.04 $0.04
15 Jul 2021 $0.04 $0.00 0.00% 3,176,495 $0.04 $0.04 $0.04
14 Jul 2021 $0.04 $0.00 0.00% 4,466,914 $0.04 $0.04 $0.04
13 Jul 2021 $0.04 $0.00 0.00% 8,059,602 $0.04 $0.04 $0.04
12 Jul 2021 $0.04 $0.00 0.00% 541,217 $0.04 $0.04 $0.04
09 Jul 2021 $0.04 $0.00 0.00% 2,487,585 $0.04 $0.04 $0.04
08 Jul 2021 $0.04 $0.00 0.00% 1,115,238 $0.04 $0.04 $0.04
07 Jul 2021 $0.04 $0.00 0.00% 4,557,707 $0.04 $0.04 $0.04
06 Jul 2021 $0.04 $0.00 0.00% 1,829,759 $0.04 $0.04 $0.04
05 Jul 2021 $0.04 $0.00 0.00% 2,229,970 $0.04 $0.04 $0.04
02 Jul 2021 $0.04 $0.00 0.00% 2,559,256 $0.04 $0.04 $0.04
01 Jul 2021 $0.04 $0.00 0.00% 3,099,505 $0.04 $0.04 $0.04
30 Jun 2021 $0.04 $0.00 0.00% 6,473,628 $0.04 $0.04 $0.04
29 Jun 2021 $0.04 $0.00 0.00% 8,547,615 $0.04 $0.04 $0.04
28 Jun 2021 $0.04 $0.00 0.00% 6,428,652 $0.04 $0.04 $0.04
25 Jun 2021 $0.04 $0.00 0.00% 2,246,677 $0.04 $0.04 $0.04
24 Jun 2021 $0.04 $0.00 0.00% 4,179,402 $0.04 $0.04 $0.04
23 Jun 2021 $0.04 $0.00 0.00% 3,659,197 $0.04 $0.04 $0.04
22 Jun 2021 $0.04 $0.00 0.00% 5,932,865 $0.04 $0.04 $0.04

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
05 Mar 2021 Brett Mitchell Cancelled 2 $165,000
Cancellation of securities. 5,000,000 - Performance Rights
05 Mar 2021 Roby Zomer Cancelled 2 $165,000
Cancellation of securities. 5,000,000 - Performance Rights
05 Mar 2021 Stephen Parker Buy 282 $9,999
On-market trade. Trading in GBP.
12 Aug 2020 Roby Zomer Buy 2 $60,000
Conversion of securities. Estimated valuation.
12 Aug 2020 Roby Zomer Exercise 2 $60,000
Conversion of securities. 7,500,000 - Performance Rights.
Estimated valuation.
12 Aug 2020 Brett Mitchell Buy 2 $60,000
Conversion of securities. Estimated valuation.
12 Aug 2020 Brett Mitchell Exercise 2 $60,000
Conversion of securities. Estimated valuation
7,500,000 - performance rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Evan Hayes Non-Executive Director Sep 2020
Mr Hayes is an experienced Board member and has over 20+ commercial and leadership experience within the healthcare and biotechnology sectors. Mr Hayes' has also won the Daniel O'Carroll Award for Scientific Research. Mr Hayes is currently the Asia Pacific Managing Director of Factors Group, Canada's natural health company. Prior to this Mr Hayes was the Director of Sourcing and Product Development at Australia's natural health company, Blackmores, leading the Procurement, Technical, New product development, and Strategic sourcing divisions. Mr Hayes was also Executive Director, Chairman of the Scientific Advisory Board and Chief Scientific Officer of BioCeuticals, part of the Blackmores group. During his career, Mr Hayes has worked across Europe, the USA and in Australia and has knowledge of both the FDA and the TGA regulation.
Mr Brett Anthony Mitchell Executive ChairmanExecutive Director Apr 2013
Mr Mitchell is a corporate finance executive with over 25 years of experience in the venture capital, capital markets, tech and resources industries. He has been part of the founding, financing and management of both private and publicly-listed companies. Mr Mitchell is a founder and director of Chieftain Securities Pty Ltd and founder and shareholder of Graft Polymer (UK) Ltd.
Dr Ross Grant Thomas Walker Non-Executive Director Feb 2016
Dr Walker has over 35 years experience as a clinician. For the past 20 years, he has been focusing on preventative cardiology.
Mr Nativ Segev Non-Executive Director Feb 2016
Mr Segev was a leader in the Medical Cannabis industry with a patient base. He has over 10 years of experience in implementation, legislation and lobbying in the global Medical Cannabis industry, combined with over 15 years of experience in executive roles.
Mr Roby Reuven Zomer Chief Executive OfficerManaging Director Feb 2016
Mr Zomer have ten years of experience in projects in the Biotech and Agrotech sectors. Over the past year, Mr Zomer has been in to solidifying the company's standing as a provider of phytomedicines in the regions globally and has launched a product, ArtemiCTM, which is from initial results proving an treatment against symptoms of COVID-19, backed by ongoing clinical trials. Additionally, he has put his engineering and medical background into play, and has put a emphasis on the company's research and development activities, and to led to possibilities of distribution and collaboration in markets around the globe.
Mr Stephen Barry Parker Non-Executive Director Mar 2019
Dr Parker is a executive with over thirty years experience in the pharmaceuticals and biotechnology sectors, as a senior executive in the sector, a strategy consultant, a venture capitalist and a senior corporate financier with Baring's, Warburg's and Apax Partners. Dr Parker is currently Chairman of Sareum Holdings plc and a non-Executive Director of Eternans Limited. He is Chairman of the Corporate Governance Committee.
Mr David Lim Joint Company Secretary Jun 2021
-
Mrs Rachel Kerr Joint Company Secretary Feb 2019
-
Rachel Kerr Joint Company Secretary
-
David Lim Joint Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Hsbc Custody Nominees (Australia) Limited 120,080,182 7.36%
MGC Pharmaceuticals Ltd 45,993,000 2.82%
Mr George Bishay 36,822,890 2.26%
Citicorp Nominees Pty Limited 30,000,091 1.84%
Mr Brett Mitchell + Mrs Michelle Mitchell <Mitchell Spring Family A/C> 22,264,444 1.36%
C Y T Investment Pty Ltd 14,000,000 0.86%
J P Morgan Nominees Australia Pty Limited 10,167,392 0.62%
Mr Shady Eskander 8,311,111 0.51%
Mr Brett Mitchell + Mrs Michelle Mitchell <Lefthanders Super Fund A/C> 8,140,560 0.50%
Mr David Clement Hobby 8,000,000 0.49%
Mr Benjamin Thomas Langley 7,388,430 0.45%
Fadco Investments Limited 6,772,613 0.42%
Mr Michael Sean Newton 6,500,000 0.40%
Netwealth Investments Limited <Wrap Services A/C> 6,042,727 0.37%
Cardaze Pty Limited <Boyle Family Super Fund A/C> 5,764,059 0.35%
Merrill Lynch (Australia) Nominees Pty Limited 5,616,522 0.34%
J & D Peos Super Pty Ltd <J & D Peos Super Fund A/C> 5,585,262 0.34%
BNP Paribas Noms Pty Ltd <DRP> 5,210,062 0.32%
Cannvalate Pty Ltd 5,139,037 0.32%
Ms Autumn Bloom 5,000,000 0.31%

Profile

since

Note